真实世界连花清瘟胶囊（颗粒）适应证人群临床特征及联合用药分析

doi:10.19803/j.1672-8629.20220069

摘要/Abstract

摘要： 目的探索真实世界中连花清瘟胶囊（颗粒）适应证人群的临床特征及联合用药情况,为该药临床用药提供参考和借鉴。方法基于医院信息管理系统（HIS）,对数据库中18家医院2002年5月20日至2019年3月20日使用连花清瘟胶囊（颗粒）的5 902例患者进行一般用药人群临床用药特征描述分析,运用关联规则,对连花清瘟胶囊（颗粒）的联合用药一并分析。结果连花清瘟胶囊（颗粒）的使用人群主要以45~65岁男性患者为主,住院天数多为15~28 d,西医诊断频次肺部感染最多,治疗结局以好转或治愈出院为主。临床上常与西药乙酰水杨酸、氨溴索、左氧氟沙星以及中药丹红注射液、痰热清注射液、喜炎平注射液等联合应用的患者。结论连花清瘟胶囊（颗粒）临床使用基本符合药品说明书,单次用药剂量大于说明书中剂量范围,体现了连花清瘟胶囊（颗粒）的用药现状;通过对合并用药分析,发现了临床常用合并治疗方案,为临床合理用药提供参考。

关键词: 连花清瘟胶囊（颗粒）, 肺部感染, 真实世界研究, 联合用药

Abstract: Objective To explore the clinical characteristics and drug combination of Lianhua Qingwen capsules (granules) in the treatment of targeted populations in the real world so as to provide reference for clinical use. Methods The clinical data on 5 902 patients treated with Lianhua Qinwen capsule (granules) in 18 hospitals in China between May 20, 2002 and March 20, 2019 was analyzed based on the Hospital Information System(HIS). The clinical characteristics of the patients were identified, and association rules were used to analyze combined medications. Results The users of Lianhua Qingwen capsules (granules) were mostly male patients aged 45 to 65, and hospital stay ranged from 15 to 28 days. The most prevalent symptoms diagnosed by western medicine were pulmonary infections. Most of the patients were improved or discharged after being cured. Clinically, Lianhua Qingwen capsules (granules) were normally used in combination with such western medicines as acetylsalicylic acid, ambroxol (methamphetamine), levofloxacin and with such traditional Chinese medicines as Danhong injection, Tanreqing injection and Xiyanping injection. Conclusion The clinical use of Lianhua Qingwen capsules (granules) generally complies with drug instructions, but the single dose is greater than the dose range in the instructions. Analysis of combined medications has revealed the commonly used combined treatment schemes in clinic, which provides reference for clinical rational medications.

Key words: Lianhua Qingwen capsules (granules), pulmonary infection, real-world study, drug combination

中图分类号:

R978
R994.11

杜莹, 谢雁鸣, 王连心, 耿洪娇, 李向杰. 真实世界连花清瘟胶囊（颗粒）适应证人群临床特征及联合用药分析[J]. 中国药物警戒, 2023, 20(3): 296-300.

DU Ying, XIE Yanming, WANG Lianxin, GENG Hongjiao, LI Xiangjie. Clinical characteristics and drug combination analysis of Lianhua Qingwen capsules (granules) in the real world[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 296-300.

参考文献

[1] WANG SH, LIU JF, ZHANG YL, et al.Systematic evaluation of the efficacy and safety of Lianhua Qingwen capsule in the treatment of viral cold[J]. Chinese Journal of Traditional Chinese Medicine(中国中药杂志), 2019, 44(7): 1503-1508.
[2] WU YL.Interpretation of Lianhua Qingwen capsule[J]. Chinese Medical Guide(中国医药指南), 2005 ,23(11): 120-121.
[3] SHI L. Clinical efficacy and safety of moxifloxacin hydrochloride sequential therapy in patients with lower respiratory tract infection[J]. China Pharmacoeconomics(中国药物经济学), 2020, 15(6): 83-85. 89.
[4] WANG Y, WANG YF, MA J, et al.Efficacy of Lianhua Qingwen Capsule combined with oseltamivir in the treatment of influenza virus infection in children and its effect on NO and IFN- γ、Effect of IL-17 expression level[J]. Chinese Journal of Traditional Chinese Medicine(中华中医药学刊), 2020, 38(1): 214-216.
[5] LI YN, XIE YM, ZHANG Y, et al.Analysis of clinical application and combined medication characteristics of compound Sophora flavescens injection in the elderly: a real-world study based on hospital information system[J]. Journal of Changchun University of Traditional Chinese Medicine(长春中医药大学学报), 2019, 35(2): 255-260.
[6] YANG W, CHENG H, XIE YM, et al.Analysis of “real world” clinical medication characteristics of erigeron breviscapus injection based on HIS[J]. Chinese Journal of Traditional Chinese Medicine(中国中药杂志), 2012, 37(18): 2718-2722.
[7] World Health Organization.International Statistical Classification of Diseases and Health-Related Problems (10th revision)(疾病和有关健康问题的国际统计分类第10次修订本)[M]//DONG JW. Beijing: People’s Medical Publishing House, 2008.
[8] National Standards of People’s Republic of China. GB/T 16751.2-1997. TCM Clinical Diagnosis and Treatment Terms-Syndrome Part(中医临床诊疗术语证候部分)[S]. Beijing: Standards Press of China, 1997.
[9] ZHAO SC, WEI RL, XIE YM, et al.Complex network analysis of 2147 cases of upper respiratory tract infection treated with Qingkailing injection in the real world[J]. Chinese Journal of Traditional Chinese Medicine(中国中药杂志), 2019, 44(23): 5207-5216.
[10] WANG FC, SHEN BX, HE CY, et al.Network pharmacology study on the clinical efficacy and mechanism of Lianhua Qingwen Granule on New Coronavirus pneumonia[J]. Pharmacology and Clinic of Traditional Chinese Medicine(中药药理与临床), 2020, 36(2): 93-101.
[11] TIAN DH.Huangdi Neijing·Su Wen(黄帝内经·素问)[M]. Beijing: People’s Health Publishing House, 2017: 1-3.
[12] SU BG. Jinguiyaolue Handout(金匮要略讲义)[M]. Beijing: Academy Press, 1995: 27, 29.
[13] Nanjing College of traditional Chinese Medicine. Translation and Interpretation of Huangdi Neijing Lingshu(黄帝内经灵枢译释)[M]. Shanghai: Shanghai Science and Technology Press,1981.
[14] ZHANG LH, YU FR, SANG WT, et al.Research status of treatment of influenza with Lianhua Qingwen[J]. Traditional Chinese Medicine and Clinic(中药与临床), 2019, 10(1): 54-58.
[15] LIP, WANG CY.Research progress on benefits and risks of aspirin in patients with chronic obstructive pulmonary disease[J]. Chinese Contemporary Medicine(中国当代医药), 2020, 27(22): 23-26.
[16] CHEN SZ.Clinical observation of ambroxol hydrochloride in the treatment of pneumonia[J]. Modern Health Preservation(现代养生), 2022, 22(14): 1151-1153.
[17] YUN Y, SHAO DF, SUN Y, et al.Lianhua Qingwen capsule combined with levofloxacin in the treatment of community-acquired pneumonia and its effect on LCQ score and inflammatory factors[J]. Journal of Difficult Diseases(疑难病杂志), 2020, 19(11): 1152-1156.
[18] LYU H, OUYANG ZN,WANG J, et al.Clinical study of Lianhua Qingwen capsule combined with levofloxacin in the treatment of pneumonia[J]. Modern Medicine and Clinic(现代药物与临床), 2018, 33(9): 2294-2297.
[19] ZHENG SH, YOU Q.Clinical observation of Danhong injection combined with western medicine in the treatment of elderly patients with acute exacerbation of chronic obstructive pulmonary disease[J]. Geriatrics and Health Care(老年医学与保健), 2022, 28(1): 135-139.
[20] LIU XY, YU WN, HE MY, et al.Clinical observation of Tanreqing injection in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease (phlegm heat blocking the lung syndrome)[J]. Chinese Journal of Critical Care Medicine(中国急救医学), 2022 , 31(3): 497-500.
[21] ZHANG JS. Observation on the efficacy of Xiyanping injection in the treatment of pediatric pneumonia[J]. World Latest Medical Information Digest(世界最新医学信息文摘), 2018, 18 (70): 132, 134.
[22] PENG ZL, XIE YM, ZHI YJ, et al.Analysis of clinical application characteristics of Salvia miltiorrhiza polyphenolate for injection in HIS[J]. Shi Zhen Guo Yi Guo Yao(时珍国医国药), 2016, 27(4): 945-947.